The participants will be pregnant women with late-onset pre-eclampsia

Pre-Eclampsia

On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).

Placental growth factor

Alex Ekwuueme Federal University Teaching Hospital

Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women

Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women in Abakaliki

Adverse maternal outcomes will include one or more of: disseminated intravascular coagulation (DIC), HELLP syndrome, abruptio placentae, pulmonary oedema, intracerebral haemorrhage, acute left ventricular failure, renal insufficiency (creatinine >90 umol/l), liver disease (aspartate aminotransferase >40 U/l), eclampsia and maternal death.

Adverse fetal outcomes will include one or more of: Apgar score <7 at the 5th minute, small-for-gestational-age infant (SGA; <10th centile), admission to special-care nursery, fetal death and early neonatal death.

The researchers plan to make the data available to other authors

Johnbosco Ifunanya Nwafor

Principal investigator

Mother-infant dyads with suspected or confirmed diagnosis of placental abruption

Healthy mother-infant dyads admitted for delivery

Whole blood for serum biomarkers and placental micro-particles.

Abruptio Placentae

University of Arkansas for Medical Sciences

Plasma Concentration of Biological Markers in Placental Abruption

Determine quantitatively the level of placental-derived MPs which may be altered in 10 subjects with PA compared to 10 matched control subjects.

Determine quantitatively the level of biomarkers which may be altered in 10 subjects with PA compared to 10 matched control subjects.

In order to evaluate the secondary outcome, the correlation between maternal serum total placental MPs, biomarkers to clinical symptomology, and the severity of placental abruption after delivery will be examined.

University of Arkansas

After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.
Control group will be treated with placebo.

50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.

Severe Pre-eclampsia

Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.

Rosuvastatin

Placebo

Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery

Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery

systolic pressure below 140mm\Hg or diastolic pressure below 90mm\Hg. Measurement will be carried out according to standard Protocol: before delivery, every 30 minutes during the first 2 hours post-delivery then every hour until discharge.

We intend to test the following metrics:
The amount and activity of NK cells in the placenta.
The rate of secretion of angiogenic factors VEGF, SFLT-1, PLGF and inflammation factors TGF-ALFA I and IL-6.

abruptio placentae/tyrosine

Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women

Plasma Concentration of Biological Markers in Placental Abruption

Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم